- 5. (Amended) A composition according to claim 1 wherein the surfactant is selected from the group consisting of a polyoxyethylene castor oil, a polyoxyethylene alkyl ether, and a polysorbate.
- 6. (Amended) A composition according to claim 1 wherein the surfactant has an HLB value of greater than 10 and the composition further comprises a co-surfactant having an HLB value of less than 10.
- therapy comprising administering a dispersible pharmaceutical composition according to claim 1 to a subject in need of such treatment.

(Amended) A method of treatment for treating subjects in need of N-benzoyl-staurosporine

13. (Amended) A method of increasing bioavailability levels or reducing variability of bioavailability levels of N-benzoylstaurosporine, said method comprising orally administering a composition according to claim 1 to fasted beagle dogs.

REMARKS

ĻÚ

L.L

1.0

í,ĝ

: =

-3

10.

Claims 3 to 6, 10 and 13 had been amended to eliminate multiple dependencies. Claims 3-6 have been amended to state more proper US claim language. Favorable consideration of this application is respectfully requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached pages are captioned "VERSIONS WITH MARKINGS TO SHOW CHANGES MADE."

Respectfully submitted,

Novartis Corporation Patent and Trademark Dept. 564 Morris Avenue Summit, NJ 07901-1027 (908) 522-6921

Date: August (4, 2001

Norbert Gruenfeld Agent for Applicants Reg. No. 30,061